Company Filing History:
Years Active: 2020-2024
Title: Yi Tian Png: Innovator in Immunotherapy
Introduction
Yi Tian Png is a prominent inventor based in Singapore, known for his significant contributions to the field of immunotherapy. He has been awarded four patents, showcasing his innovative approach to cancer treatment through engineered immune cells.
Latest Patents
His latest patents include groundbreaking inventions aimed at enhancing cancer therapies. The first patent focuses on the blockade of CD2 surface expression and the expression of chimeric antigen receptors for immunotherapy of T-cell malignancies. This invention provides engineered immune cells that comprise an anti-CD2 protein expression blocker and an anti-CD2 chimeric antigen receptor. In certain embodiments, these engineered immune cells lack surface expression of CD2, offering new methods for cancer therapies. The second patent addresses the blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies. This invention includes compositions that comprise an anti-CD7 chimeric activating receptor and an anti-CD7 protein expression blocker, along with methods for utilizing these compositions in cancer therapy.
Career Highlights
Yi Tian Png is affiliated with the National University of Singapore, where he continues to advance research in immunotherapy. His work has garnered attention for its potential to revolutionize treatment options for T-cell malignancies.
Collaborations
He collaborates with notable colleagues, including Natasha Vinanica and Takahiro Kamiya, contributing to a dynamic research environment focused on innovative cancer therapies.
Conclusion
Yi Tian Png's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work promises to make a significant impact on cancer treatment methodologies.